arrow
Return

Dedicated research navigators: a tool to decrease disparities in clinical trial enrollment?

delete2025-02-01
delete0
PRE
AI
T
Teresa Boitano *
J
Jaclyn Wall
L
Lia Bos
G
Gabrielle B. Rocque
C
Courtney Williams
H
Haller J. Smith
J
J. Michael Straughn
C
Charles A. Leath
W
Warner K. Huh
R
Rebecca C. Arend
DOI:10.1016/j.ijgc.2024.100066delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Objective: The goal of this study was to evaluate the impact of a formalized research team and screening process on racial disparities associated with clinical trial enrollment at a tertiary academic center. Methods: We conducted a retrospective cohort study of patients with gynecologic malignancies approached for clinical trial enrollment from March 2018 to February 2022. A dedicated research navigator team and protocol were implemented to review and approach all (potentially) eligible clinical trial patients. The control group consisted of patients enrolled prior to the research navigator team. A survey was also performed in the research navigator team group to evaluate the reasons why patients decline clinical trials. Analysis was performed using SPSS version 26. Results: A total of 411 patients were included in this cohort with 187 in the control group and 224 in the research navigator team. There was a high rate of minority inclusion with 27.3% of patients being Black. Enrollment in the clinical trials increased from 15.0% to 36.9% after the initiation of the research navigator team. Patients were more likely to enroll if they had recurrent disease vs primary disease (p < .001). The most common reasons for patients declining clinical trials were the desire to receive treatment locally (25.0%), concern about the trial (21.7%), and wanting to receive the standard of care treatment (15.0%). Conclusions: Using a dedicated research navigator team increased the identification of eligible patients and decreased racial disparities in clinical trial enrollment at our tertiary academic center. The most common reason women declined enrollment was to receive treatment locally. Continued identification of barriers to trial enrollment remains paramount in working to improve outcomes for gynecologic oncology patients.
Keywords:
Health Equity
Disparities
Survival Outcomes
Clinical Trials
Cancer

Journal

International Journal of Gynecological Cancer cover
International Journal of Gynecological Cancer
IF:
4.7
Papers:
1.5K
Citations:
1.1W

Organization

U
Univ Alabama Birmingham
Scholars:
1.5K
Papers: 1.6K
Citations: 192
Cited Papers

Cited Papers

Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials
err2024-02-01
err0
PREAI
errMichael T. Richardson; Danika Barry; Jecca R. Steinberg; Vineeth Thirunavu; Danielle E. Strom; Kai Holder; Naixin Zhang; Brandon E. Turner; Christopher J. Magnani; Brannon T. Weeks; Anna Marie P. Young; Connie F. Lu; Tierney R. Wolgemuth; Nora Laasiri; Natalie A. Squires; Jill N. Anderson; Beth Y. Karlan; John K. Chan; Daniel S. Kapp; Dario R. Roque; Ritu Salani
errShare
errSave
Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
err2024-09-13
err0
PREAI
errBhavana Pothuri; Premal Thaker; Adrienne Moore; Rosa Espinosa; Kara Medina; Deborah Collyar; Kathleen Lutz; Mihaela C Munteanu; Brian Slomovitz
errShare
errSave
errShare
errSave
Improving Clinical Trial Enrollment - In the Covid-19 Era and Beyond
err2020-10-08
err36
PREAI
errNorth, Crystal M.; Dougan, Michael L.; Sacks, Chana A.
errShare
errSave
Minority participation in Gynecologic Oncology Group (GOG) Studies
err2015-08-01
err0
errOAAI
errJennifer Scalici; Michael A. Finan; Jennifer Black; Mary Danner Harmon; William Nicolson; Heather A. Lankes; William E. Brady; Rodney P. Rocconi
errShare
errSave
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)
err2023-07-01
err0
PREAI
errB. Pothuri; S.V. Blank; T.K. Myers; J.F. Hines; L.M. Randall; R.E. O'Cearbhaill; B.M. Slomovitz; R.N. Eskander; A. Alvarez Secord; R.L. Coleman; J.L. Walker; B.J. Monk; K.N. Moore; D.M. O'Malley; L.J. Copeland; T.J. Herzog
errShare
errSave
Patient navigation and clinical trial participation: A randomized controlled trial design
err2018-12-01
err0
errOAAI
errMelissa Kurtz Uveges; Dina George Lansey; Olive Mbah; Tamryn Gray; Lisa Sherden; Jennifer Wenzel
errShare
errSave
Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials
err2016-06-01
err0
errOAAI
errMona N. Fouad; Aras Acemgil; Sejong Bae; Andres Forero; Nedra Lisovicz; Michelle Y. Martin; Gabriela R. Oates; Edward E. Partridge; Selwyn M. Vickers
errShare
errSave
US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials
err2019-04-01
err0
errOAAI
errJeanne M. Regnante; Nicole A. Richie; Lola Fashoyin-Aje; Michelle Vichnin; Marvella Ford; Upal Basu Roy; Kenneth Turner; Laura Lee Hall; Evelyn Gonzalez; Nestor Esnaola; Luther T. Clark; Homer C. Adams; Olatunji B. Alese; Keerthi Gogineni; Lorna McNeill; Daniel Petereit; Ify Sargeant; Julie Dang; Coleman Obasaju; Quita Highsmith; Simon Craddock Lee; Spencer C. Hoover; Erin L. Williams; Moon S. Chen
errShare
errSave
researcher View more